Annual Recurring Revenue (ARR) Growth
Exited 2025 with ARR of $636M, up 10% from the 2024 exit rate; 2026 year-end ARR guidance of $680M–$700M (projected ~7%–10% growth vs. 2025 exit).
Full-Year Revenue Growth and Guidance
Full year 2025 total revenue was $1.185B (up from $1.112B in 2024, roughly +6.6%) and 2026 revenue guidance of $1.215B–$1.255B reflects continued growth.
Bookings and Backlog Performance
Full-year 2025 product bookings of $535M landed above the midpoint of guidance; product backlog exited 2025 at $640M (down ~1% year-over-year) with $435M short-term backlog expected to convert in 2026.
Product & Platform Innovation Momentum
Launched Titan XT and advanced Omnisphere (achieved high-trust CSF I one certification); positive early customer feedback from ASHP and notable wins (large health systems, VA, Canadian providers). Management reports a strengthened top-of-funnel and competitive traction.
Service Revenue Strength
Full year 2025 service revenue was $519M (up from $482M in 2024, +7.7%); Q4 2025 service revenue $134M, up 8% YoY — contributing to recurring revenue expansion.
Product Revenue Growth (Full Year)
Full year 2025 product revenue was $666M versus $631M in 2024, an increase of ~5.6% year-over-year, driven by connected device demand (XT family).
Profitability Run-Rate and 2026 Profit Guidance
Non-GAAP EBITDA for full year 2025 was $140M (up from $136M in 2024, +2.9%). 2026 non-GAAP EBITDA guidance of $145M–$160M signals continued expansion, and non-GAAP EPS guidance of $1.65–$1.85 indicates modest improvement potential.
Operational Improvements and Receivables
Days Sales Outstanding improved to 65 days in 2025 from 77 days in 2024, indicating better collections and working capital management.